Hansa Biopharma AB — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications22liées

SourceDBlocale

Traitements

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Anti-CD20 antibodiesAn open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care	SEP	Phase 3	Immunomodulation	United States	À vérifier
eculizumabThe purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.	Myasthénie, SEP	Phase 3	À vérifier	United States	À vérifier
IvIgInflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical effect of IvIg in post-polio syndrome.	Myopathies, SEP	Phase 3	Traitement symptomatique	United States	À vérifier
PLEXAn open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care	SEP	Phase 3	À vérifier	United States	À vérifier
eculizumabThe purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.	Myasthénie	Phase 2	À vérifier	United States, Canada, United Kingdom	À vérifier
IvIgInflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical effect of IvIg in post-polio syndrome.	Myopathies	Phase 2	Traitement symptomatique		À vérifier

Essais cliniques

Molécule	Indication / population	Phase	NCT	Titre	Statut
imlifidase	SEP	Phase 3	NCT04935177	ConfIdeS — Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx	COMPLETED
IvIg	Myopathies	Phase 2	NCT00231439	Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)	COMPLETED
eculizumab	Myasthénie	Phase 2	NCT00727194	Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis	TERMINATED

Publications

Molécule	Titre	Journal
eculizumab	Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.	Hematology (Amsterdam, Netherlands)
eculizumab	Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.	Hematology (Amsterdam, Netherlands)
IvIg	Anti-GAD65 antibody-associated cerebellar ataxia in a young adult with type 1 diabetes: a case report and literature review.	Diabetology international
IvIg	The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review.	Journal of medical economics
IvIg	SARS-CoV-2-induced IgG repertoires shape T cell responses, microRNA regulation, and autoreactivity according to disease severity.	Journal of translational autoimmunity
eculizumab	Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases.	Frontiers in immunology
IvIg	When Neurodevelopment Meets Autoimmunity: Pemphigus Foliaceus in Rett Syndrome Expands the Clinical Spectrum-A Case Report.	International journal of molecular sciences
IvIg	Guillain-Barré syndrome with bilateral extensor plantar responses: A rare case report.	Journal of family medicine and primary care
eculizumab	Systemic lupus erythematosus complicated by thrombotic microangiopathy with atypical HUS features: A case report.	Medicine
IvIg	A case report of Good syndrome: Diarrhea and dyspnea.	Medicine
IvIg	Knowledge graph visualization and bibliometric analysis of research on coronary artery lesions in Kawasaki disease.	Medicine
IvIg	Immune-Related Adverse Events From Checkpoint Inhibitors: An Evidence-Based Management Review.	Critical reviews in oncology/hematology
IvIg	Intravenous Immunoglobulin-Resistant Kawasaki Disease: Diagnosis, Mechanisms, and Clinical Management.	European journal of pharmacology
IvIg	Fulminant toxic epidermal necrolysis induced by pucotenlimab in a patient with lung adenocarcinoma: a case report.	Frontiers in oncology
IvIg	Guillain-Barré Syndrome Following Dengue Infection: A Case Series with Review of Literature.	Annals of neurosciences
eculizumab	[Atypical hemolytic uremic syndrome: key points in differential diagnosis and recent advances in treatment].	[Rinsho ketsueki] The Japanese journal of clinical hematology
eculizumab	Complement System Inhibitors in Nephrology: A Comprehensive Review.	Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
IvIg	Early postoperative onset of immune thrombocytopenia in rheumatoid arthritis with concomitant systemic lupus erythematosus: a case report.	Modern rheumatology case reports
IvIg	Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation.	Frontiers in medicine
eculizumab	Long-term eculizumab treatment failure in C3 glomerulonephritis: two case reports.	Clinical kidney journal
eculizumab	Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany.	BMC nephrology
eculizumab	A case report of atypical hemolytic uremic syndrome with a CFH mutation complicated by recurrent posterior reversible encephalopathy syndrome.	Medicine